华森制药获得特医食品生产许可

Group 1 - The core point of the article is that Chongqing Huasen Pharmaceutical Co., Ltd. has received a production license for special medical purpose formula foods, which supports the production of its product "Ganyimei®" [1] - The product "Ganyimei®" is designed for individuals over 10 years old who require strict fat restrictions and have digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber, primarily composed of carbohydrates with a high energy supply ratio of 87% [1] - The product is applicable in various scenarios, including nutritional support for acute pancreatitis, short bowel syndrome, and gastrointestinal function damage, as well as standardized liquid diets before colonoscopy [1] Group 2 - According to Grand View Research, the global special medical food market is projected to reach $24.8 billion in 2024 and grow at a compound annual growth rate (CAGR) of 5.13% to $33.49 billion by 2030 [2] - The Chinese market is expected to be approximately 16.4 billion RMB in 2024, accounting for 9.15% of the global market share, with a projected CAGR of 6.58% to reach 24 billion RMB by 2030 [2] - The clinical usage rate of special medical foods in China is currently much lower than in developed countries, indicating significant growth potential as health awareness and clinical nutritional support needs increase [2] - The production license change is a foundational step for the company to expand its special medical food business and is an important measure for enhancing its health industry layout [2]